共 27 条
- [21] Randomized phase Ill study comparing FOLFOX plus bevacizumab versus folfoxiri plus bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Sastre, JavierMaria Vieitez, JoseAuxilidora Gomez-Espana, MariaGil Calle, SilviaSalud Salvia, AntonietaGrana Suarez, BegonaGarcia-Alfonso, PilarMartinez de Castro, EvaQuintero Aldana, Guillermo AlfonsoJose Reina-Zoilo, JuanGonzalez Flores, EncarnacionSalgado Fernandez, MercedesGuillen, CarmenGarcia-Carbonero, RocioJose Safont, MariaLa Casta Munoa, AdelaidaGarcia de Paredes, BeatrizLopez, RafaelAranda, EnriqueDiaz-Rubio, Eduardo
- [22] Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)Johnson, Bruce E.Kim, Tae MinHiltermann, T. Jeroen N.Barlesi, FabriceGrohe, ChristianGoto, YasushiGunnarsson, OrvarOverbeck, TobiasReguart, NoemiWermke, MartinCastro, GilbertoFelip, EnriquetaGreystoke, AlastairSolomon, Benjamin J.Nebot, NoeliaDeudon, StephanieLouveau, Anne-LaurePassos, Vanessa Q.Tan, Daniel S. W.
- [23] Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IVBLOOD, 2010, 116 (21) : 162 - 163Hanfstein, BenjaminMueller, Martin C.Erben, PhilippSchnittger, SusanneSaussele, SusanneLeitner, ArminProetel, UlrikeEhninger, GerhardHossfeld, Dieter K.Kolb, Hans-JochemKrause, Stefan W.Nerl, ChristophPralle, HansHeim, DominikBaerlocher, Gabriela M.Heimpel, HermannHehlmann, RuedigerHochhaus, Andreas
- [24] Safety analysis of a phase III randomized trial comparing FOLFOX plus Bevacizumab vs FOLFOXIRI plus Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNU-1 TTD TRIAL).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Gomez, A.Vieitez, Jose MariaGil, SilviaSalvia, Antonieta SaludSuarez, Begona GranaAlfonso, Pilar GarciaMartinez de Castro, EvaQuintero Aldana, Guillermo AlfonsoReina, Juan J.Gonzalez Flores, EncarnacionSalgado Fernandez, MercedesRodriguez Garrote, MercedesFlor Oncala, Ma JoseJose Safont, MariaLa Casta Munoa, AdelaidaLopez, RafaelMonica, GuillotGarcia-Paredes, BeatrizDiaz-Rubio, EduardoAranda, Enrique
- [25] COMBINING THE ANTIGEN-PRESENTING CELL ACTIVATOR EFTILAGIMOD ALPHA (SOLUBLE LAG-3) AND PEMBROLIZUMAB: EFFICACY RESULTS FROM THE 1ST LINE NON-SMALL CELL LUNG CANCER COHORT OF TACTI-002 (PHASE II)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1529 - A1529Iams, WadeFelip, EnriquetaMajem, MargaritaDoger, BernardClay, TimCarcereny, EnricBondarenko, IgorPeguero, JulioCobo-Dols, ManuelForster, MartinUrsol, GrygoriiKalinka, EwaLedo, Gema GarciaMartinez, Laia VilaKrebs, MatthewBalea, Begona CamposKefas, JoannaMueller, ChristianBrignone, ChrystelleTriebel, Frederic
- [26] CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLCONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152Grohe, C.Johnson, B. E.Kim, T. M.Hiltermann, T. J. N.Barlesi, F.Goto, Y.Gunnarsson, O.Overbeck, T.Reguart, N.Wermke, M.de Castro, G., Jr.Felip, E.Greystoke, A.Solomon, B. J.Deudon, S.Louveau, A. -L.Passos, V.Tan, D. S. W.
- [27] ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY, 2016, 27Popat, S.Tiseo, M.Gettinger, S.Peters, S.Haney, J.Kerstein, D.Camidge, D. R.